Hei Chan

诺辉健康 New Horizon Health Limited

New Horizon Health Limited (Incorporated in the Cayman Islands with limited liability) Company Overview Founded in 2015, New Horizon Health is the pioneer and leader in China's cancer screening market, with a vision to prevent and cure cancer by screening and early detection. Company has two commercialized medical tests for colorectal cancer screening, and two late-stage pipeline candidates for gastric and cervical cancer screening respectively. Company holds global rights to all its marketed and pipeline products. A home-based, non-invasive, national-guideline-recommended FIT-DNA test targeting 120 million colorectal high-risk population in China, ColoClear is the first and only cancer screening test approved by NMPA. Pupu Tube, NMPA approved and CE Mark obtained, is the first self-conducted FIT screening test targeting 630 million population to identify colorectal high-risk individuals in China. In addition, Company has a synergistic screening pipeline portfolio focusing on high-incidence cancer types in China. Goldman Sachs (Asia) L.L.C. and UBS Securities Hong Kong Limited are the Joint Sponsors. Company Strengths -Pioneer and the only player with NMPA-approved products in China's cancer screening market, which has a high entry barrier protected by technical, clinical, and regulatory hurdles. -ColoClear as the first and only colorectal cancer screening test validated by large-scale prospective registrational trial in China, offering tremendous clinical utility and social value -Focused and synergistic cancer screening portfolio, including late-stage pipelines focusing on high-incidence cancer types in China -Multi-pronged commercialization approach to maximize the potential of ColoClear and Pupu Tube. -Visionary and experienced management team supported by strong healthcare investors. Company Strategies -Further develop the cancer screening market in China. -Increase market penetration of ColoClear and Pupu Tube in China.